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Abstract
Background: Leucine-rich repeat kinase 2 (LRRK2) is a common gene implicated in Parkinson’s disease (PD) and is
also thought to be fundamentally involved in numerous immune functions. Thus, we assessed the role of LRRK2 in
the context of the effects of the environmental toxicant, paraquat, that has been implicated in PD and is known to
affect inflammatory processes.
Methods: Male LRRK2 knockout (KO) and transgenic mice bearing the G2019S LRRK2 mutation (aged 6–8 months)
or their littermate controls were exposed to paraquat (two times per week for 3 weeks), and sickness measures,
motivational scores, and total home-cage activity levels were assessed. Following sacrifice, western blot and ELISA
assays were performed to see whether or not LRRK2 expression would alter processes related to plasticity, immune
response processes, or the stress response.
Results: Paraquat-induced signs of sickness, inflammation (elevated IL-6), and peripheral toxicity (e.g., organ weight)
were completely prevented by LRRK2 knockout. In fact, LRRK2 knockout dramatically reduced not only signs of illness,
but also the motivational (nest building) and home-cage activity deficits induced by paraquat. Although
LRRK2 deficiency did not affect the striatal BDNF reduction that was provoked by paraquat, it did blunt the
corticosterone elevation induced by paraquat, raising the possibility that LRRK2 may modulate aspects of
the HPA stress axis. Accordingly, we found that transgenic mice bearing the G2019S LRRK2 mutation had
elevated basal corticosterone, along with diminished hippocampal 5-HT1A levels.
Conclusion: We are the first to show the importance of LRRK2 in the peripheral neurotoxic and stressor-like effects
of paraquat. These data are consistent with LRRK2 playing a role in the general inflammatory tone and stressor effects
induced by environmental toxicant exposure.
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Background
Virtually, all neurological diseases have an inflammatory
component that in some regard is associated with the
manifestation of a range of primary and/or co-morbid
symptoms. Parkinson’s disease (PD) is no exception hav-
ing a prominent neuroinflammatory element, along with
the range of behavioral and autonomic symptoms, in
addition to primary motor deficits [1, 2]. Among the
genes implicated in both PD and its inflammatory
processes, leucine-rich repeat kinase 2 (LRRK2), and in
particular its G2019S mutation, has received consider-
able attention [3–5]. In fact, the highest levels of LRRK2
were found in peripheral lymphocytes and monocytes of
PD patients [6], and LRRK2 mutations have been associ-
ated with microglial reactivity and pro-inflammatory
cytokine production in the brain and periphery [7–10].
Moreover, typical inflammatory agents, such as lipopoly-
saccharide (LPS), as well as chemical toxicants like
MPTP, that are used to model PD pathology have been
shown to influence processes linked to LRRK2 [11–13].
Accordingly, LRRK2 may be a critical general mediator
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of inflammatory pathology associated with a range of en-
vironmental insults.
Numerous reports have implicated environmental tox-
icants in the development of PD, and in particular, in-
creased incidence of PD has been associated with
exposure to various pesticides [14–17]. Indeed, animal
studies have confirmed that the herbicide and oxidative
stress generating chemical, paraquat, provokes a loss of
midbrain dopamine neurons, coupled with a range of
behavioral symptoms [18–21]. Strikingly, the impact of
pesticide exposure may be modified by genetic back-
ground [22–24]. Given the highly variable penetrance of
LRRK2 mutations [25, 26], it is likely that environmental
stressor exposure of some sort may be required in the
context of LRRK2 mutation to provoke a disease state.
This is in keeping with the idea that multiple hits give
rise to PD; in effect, LRRK2 mutation could “set the
stage” or essentially act as the first of such hits over
one’s lifetime. Further still, endogenous LRRK2 could
underlie the impact of numerous environmental hits by
virtue of its role as a modulator of inflammatory im-
mune processes.
The most common LRRK2 mutation linked to PD is
the G2019S mutation that is not only associated with
the familial form of the disease, but also might act as a
risk factor for the idiopathic form of the disease [27, 28].
This mutation is thought to cause a gain of function for
the kinase activity of LRRK2, and mice bearing this mu-
tation were reported to show alterations in dopamine
levels and enhanced sensitivity to MPTP treatment, as
well as increased α-synuclein inclusions [12, 29]. Yet, the
literature is mixed with some reports finding no differ-
ences in neurodegeneration in G2019S mutants [30].
Interestingly, the G2019S mutation might also increase
inflammatory myeloid cell responses to lipopolysacchar-
ide (LPS) [31].
The present focus was on the impact of LRRK2 defi-
ciency and G2019S mutation in response to paraquat.
Since paraquat-induced sickness symptoms and behav-
ioral features akin to what is often evident with immune
challenges, such as those induced by LPS or TNF-α [32],
we sought to evaluate whether LRRK2 knockout (KO)
and G2019S transgenic expression would affect the im-
pact of the pesticide on these outcomes. Similarly, it was
also of interest to assess whether paraquat provokes al-
terations in hormonal (corticosterone), neurotransmitter
(5-HT1A), trophic (BDNF), and inflammatory (CX3CR1,
WAVE2) factors and again whether LRRK2 plays a role.
Indeed, we previously found paraquat to reduce BDNF
levels [32–34] and a recent report linked LRRK2 muta-
tions to depressive-like symptoms that were correlated
with 5-HT1A changes [35]. Members of our group also
recently found that the actin regulatory factor, WAVE2,
controls macrophage inflammatory response through
LRRK2 [36]. Hence, it was expected that the paraquat
would not only induce brain changes, but would also
have systemic consequences that would involve changes
in peripheral inflammatory factors (IL-6) and possibly at
the organ level. We presently found that LRRK2 KO
prevented motor impairment and signs of peripheral
toxicity/stress, including sickness, weight loss, cortico-
sterone, and IL-6 elevations, as well as organ changes in
paraquat-treated aged mice. Furthermore, transgenic
G2019S overexpression basally altered striatal BDNF,
hippocampal 5-HT1A, and corticosterone levels, consist-
ent with a “stress phenotype.” Thus, it appears that
LRRK2 is an important regulator of paraquat which pro-
voked peripheral and central effects and may be relevant
for neuroimmune toxicity in general.
Methods
General study design
Briefly, two parallel studies were conducted on 6–
8-month-old LRRK2 KO (JAX# 012444) or BAC trans-
genic G2019S (JAX #012467) mice along with their re-
spective wild-type (WT) littermate controls that were
obtained from our in-house breeding colony. Prior to
the commencement of the study, baseline home-cage ac-
tivity was carried out as described below. Mice were
then randomly assigned to one of the four experimental
conditions in each of the two studies: study 1 (WT/sa-
line vs WT/paraquat and KO/saline vs KO/paraquat)
and study 2 (WT/saline vs WT/paraquat and G2019S/
saline vs G2019S/paraquat). These were analyzed as two
separate two-way ANOVAs. Saline and paraquat injec-
tions (10 mg/kg; 1,1′-dimethyl-4,4-bipyridinium dichlor-
ide; Sigma-Aldrich, St. Louis, MO, USA) began 1 day
after baseline locomotor measurements and were given
every other day for a total of six injections. Motor be-
havior alterations, assessing home-cage locomotor activ-
ity, and fine movement coordination were carried out at
various time points as described below. At the end of
the experimental paradigm, all animals were rapidly de-
capitated 1 h following the final injection.
This study used mice that were relatively older (6–8
months) than what we typically use (2–3 months), in
order to determine whether LRRK2 is important for the
toxic effects of paraquat exposure in slightly older ani-
mals. Prior to the main study presented, we initially
sought to utilize our dual-hit PD model [37]; however,
an initial study revealed profound sickness and mortality
in 6–8-month-old mice that received intra-substantia
nigra (SNc) infusion of LPS (2 μg) followed 2 days later
by nine injections of paraquat (10 mg/kg three times per
week). Remarkably, however, this toxicity was greatly di-
minished in LRRK2 KO mice. Owing to the enhanced
mortality, we decided to omit the LPS infusion and cur-
tail the number of injection down to six for the paraquat
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treatment in these mice in order to explore in detail the
role of LRRK2 in pathology. Indeed, the mortality/sick-
ness was typically observed by the sixth injection and
this regimen allowed us to ascertain whether LRRK2 KO
and/or overexpression of the most common mutation
G2019S might impact paraquat toxicity and stressor-like
effects.
Animals
C57BL/6 N-Lrrk2tm1.1Mjff/J KO and B6.Cg-Tg
(Lrrk2*G2019S)2Yue/J transgenic mice were pur-
chased from Jackson Laboratories concurrently with
C57Bl/6 J mice at 6 weeks of age. All animals were
fed Harlan Labs 2018 rodent chow and housed under
a normal 12-h light-dark cycle. Males were each
mated with 3 females in a harem breeding arrange-
ment until pregnant. At 21 days of age, male pups
were ear punched for identification, were placed on
Harlan labs 2018 diet and had tail snips taken for
genotyping. A total of 48 males from each transgenic
line were group housed with littermates and enrich-
ment in individually ventilated cages until 10 weeks of
age when they were transferred into an experimental
room and group housed until 6–8 months of age at
which point they entered the experiment.
For all mice, DNA was extracted from 0.25 cm long
tail snips collected at 21 days of age using the Qiagen
DNEasy blood and tissue kit. For LRRK2 KO mice,
animal genotype was determined via gel electrophor-
esis following DNA amplification. For G2019S trans-
genic mice, extracted DNA was analyzed using a
BioRad CFX qPCR machine and the recommended
Jackson Labs protocol to separate WT animals and
heterozygous transgenics based on melt curve data.
Pure WT products resulted in melt peaks at 80 °C
and heterozygous and homozygous transgenic ampli-
con products resulted in melt peaks at 84 °C.
Behavioral analyses
Spontaneous home cage locomotor activity assessment
was completed following a 30-min acclimation period in
our behavioral testing room, measurements of home-cage
locomotor activity occurred once at baseline (day 0), then
again the evening of the second and fifth injection.
Sickness scoring
Sickness symptoms (e.g., ptosis, curled body posture,
piloerection) were assessed daily throughout the injec-
tion regimen, as previously described [38]. Briefly, ani-
mals were assessed for the presence of the following
symptoms: ptosis (drooping eyelids), piloerection, curled
body posture, and diminished locomotion and/or ex-
ploratory behavior. Upon assessment, a score based on
the number of symptoms present (0 = no sickness
symptoms, 1 = one symptom, 2 = two symptoms, 3 =
three symptoms) was applied. Ratings were scored by an
observer blind to all experimental conditions.
Nestlet test
In order to assess goal-directed behavior alterations
involving fine motor coordination skills in mice, the
nestlet test was used, as previously described [39].
Briefly, 1 day following the second and fifth injection,
mice were placed into new standard polypropylene
cages (27 × 21 × 14 cm) containing one fully intact
nestlet (Ancare, Bellmore, NY) beginning at 08:30.
Mice nestlet building behavior was then examined
based on the quality of nest built at 1, 3, 5, and 24 h
by an investigator blind to all experimental condi-
tions. All scoring was based on the nestlet Likert rat-
ing scale whereby scores range from 0 (untouched
intact nest) to 6 (perfectly developed nest) [39].
Home-cage locomotor activity
Spontaneous home cage locomotor activity was mea-
sured over a complete 12-h light/dark cycle using our
Micromax (MMx) infrared beam-break apparatus
(Accuscan Instruments, Columbus, OH, USA), as previ-
ously described [33]. Spontaneous home cage locomotor
activity assessment was completed following a 30-min
acclimation period in our behavioral testing room post
nestlet removal, measurements of home-cage locomotor
activity occurred once at baseline (day 0), then again the
evening of the second and fifth injection.
Brain dissection and tissue extraction
Half the animals were intraperitoneally administered
200 mg/kg of sodium pentobarbital and perfused with
4% paraformaldehyde. Twenty-four hours later, the
brains were transferred to 10% sucrose and then trans-
ferred to 30% sucrose 48 h after sacrifice. The remaining
animals were sacrificed via rapid decapitation, and trunk
blood, brains, and organs were extracted and flash fro-
zen at − 80 °C.
Following rapid decapitation, brains were excised and
sectioned into sequential coronal slices using razor
blades and a chilled stainless steel microdissecting
matrix with adjacent slots spaced ~ 0.5 mm apart. Hol-
low biopsy needles were then used to collect the dorsal
striatum, hippocampus, and SNc. The tissue was imme-
diately frozen upon dissection and was stored at − 80oC
until processing. Additionally, for the LRRK2 KO study,
immediately following sacrifice, the animals’ left lung,
spleen, and liver were extracted from the cavity and any
excess fat was removed and organs were promptly
weighed. The organs were then weight and stored on
dry ice and stored at 80oC until processing.
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Plasma corticosterone assay
At the time of decapitation, trunk blood from all of the
animals was collected in tubes containing 10 μg EDTA.
Samples were centrifuged (3000g for 8 min), and the
plasma removed and stored in aliquots at − 80 °C for
later corticosterone determination with commercially
available radioimmunoassay kits (ICN Biomedicals, CA,
USA). Samples were assayed in duplicate within a single
run to control for inter-assay variability; the intra-assay
variability was less than 10%.
Plasma determination of IL-6
Trunk blood was collected at the time of decapitation
and prepared as for the corticosterone assay in a separ-
ate aliquot at − 80 °C. IL-6 levels were determined using
a Luminex Immunoassay (R&D Systems, NE, USA) ran
following kit instructions on a Luminex Magpix (Lumi-
nex Corporation, TX, USA). Samples were assayed in
duplicate within a single run to control for inter-assay
variability; the intra-assay variability was less than 10%.
Western blot
Brain tissue punches and organs were collected to detect
levels of BDNF (R&D Systems, MAB248), 5-HT1A
(Genetex, GTX104703), CX3CR1 (Sigma-Aldrich,
SAB3500204), and WAVE2 (Cell Signaling Technology,
3659), as previously described previously. Briefly, whole
cell lysates were homogenized in Radio Immuno Precipi-
tation Assay (RIPA) buffer [50 mM Tris (pH 8.0), 150
mM sodium chloride, 0.1% sodium dodecyl sulphate
(SDS), 0.5% sodium deoxycholate, and 1% Triton X-100]
mixed with 1 tablet of Complete Mini ethylenediamine-
tetraacetic acid (EDTA)-free protease inhibitor (Roche
Diagnostics, Laval, QC, Cat #11 836 170 001) per 10 mL
of buffer. On day 1 of analysis, proteins were separated
using sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE). In order to determine total pro-
tein, membranes were incubated in REVERT total
protein solution for a period of 5 min followed by place-
ment into a REVERT wash solution (6.7% glacial acetic
acid, 30% methanol, in water) two times 2 min each.
Membranes were then quickly rinsed with distilled water
and imaged on our LI-COR Odyssey imaging system on
the 700 channel for an exposure period of 2 min. Mem-
brane incubation with rabbit anti-BDNF, WAVE2,
5-HT1A, and CX3CR1 (1:1000) for a period of 60 min in
0.05% fish gelatin in TBS with 0.1% tween followed by 1
h in infrared anti-rabbit conjugate at a concentration of
1:20,000 in 0.5% fish gelatin solution containing 0.2%
tween and 0.01% SDS. Any unbound antibody was re-
moved using 15 mL of TBS-T/membrane, and mem-
branes washed and read on our Licor Odyssey system at
the appropriate wavelength for 6 min.
Statistical analysis
All data was analyzed by 2 (genotype; WT vs. KO or
WT vs G2019S) × 2 (injection; saline vs. paraquat)
two-way ANOVA with significant interactions further
analyzed by means Bonferroni follow-up comparisons (p
< 0.05) where appropriate. Additionally, analysis of total
home cage locomotor activity, sickness scores, and nest-
let building behavior was completed using appropriate
repeated measures ANOVA’s conducted with time as the
third independent variable followed by a post hoc ana-
lysis. Data is presented in the form of mean ± standard
error mean (mean ± SEM). All data was analyzed using
the statistical software StatView (version 6.0), and differ-
ences were considered statistically significant when p <
0.05.
Results
LRRK2 KO prevented paraquat and LPS + paraquat-
induced sickness behavior and mortality
A preliminary study showed that by the ninth paraquat in-
jection, a significant degree of mortality was observed in
6–8-month-old WT but not LRRK2 null mice (Fig. 1a).
Indeed, significantly more WT mice that received para-
quat treatment became moribund and hence reached end-
point compared to LRRK2 KOs or saline-treated mice (p
< 0.05). This striking finding suggested that LRRK2 might
have a fundamental role in processes aligned with inflam-
matory toxicity and hence, we reduced our paraquat injec-
tion regimen from nine to six injections. This allowed for
better survival and determination of the impact of LRRK2
with regard to behavioral and systemic outcomes normally
associated with immune and stress challenges. To this
end, LRRK2 deficient and WT littermates between 6 and
8months of age received paraquat (10mg/kg; ip) or
vehicle injection twice a week for 3 weeks. Moreover, a
parallel study using 6–8-month-old transgenic mice over-
expressing LRRK2 G2019S (which displays enhanced
LRRK2 kinase activity) was also conducted using an iden-
tical paraquat injection regimen.
In agreement with the mortality finding, LRRK2 KO
also prevented paraquat-induced signs of illness. Specific-
ally, the repeated measures two-way ANOVAs revealed a
genotype × injection interaction for scores of sickness
(F(4,128) = 10.642, p < 0.001) and animal weights
(F(5,160) = 8.319, p < 0.001) (Fig. 1b, d). Follow-up ana-
lyses revealed that beginning 1 day after the fifth injection,
WT mice treated with paraquat had significantly lower
weight and displayed higher sickness scores, relative to
their saline-exposed littermates (p < 0.05), as well as with
respect to LRRK2 null mice exposed to the toxin (p <
0.05). Correspondingly, the paraquat treatment pro-
moted significant differences in weight (F(1,57) =
21.482, p < 0.001) and sickness ratings (F(1,52) =
13.05, p < 0.05) between the groups in the parallel
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G2019S study (Fig. 1c, e). However, in this case, the
paraquat-induced signs of illness were not affected by
the G2019S genotype. Indeed, the G2019S mutant
mice appeared identical to their WT counterparts in
their sickness response to paraquat. These findings
suggest a role for endogenous LRRK2 in basic pro-
cesses aligned with the development of sickness but
that enhancement of its kinase activity does not add
to such pathology.
LRRK2 KO prevented paraquat-induced home-cage motor
activity and nestlet building deficits
A genotype × injection interaction was observed for
home-cage motor activity after the fifth paraquat injection
(F(3,25) = 3.196, p < 0.05). Indeed, paraquat-treated WT
mice displayed significantly less home-cage activity over a
24-h period (p < 0.05), but LRRK2 KO prevented this
motor reduction (Fig. 2a). We also assessed nestlet (cage
material used to construct a nest) building behavior, as
this requires fine motor skills and is also linked to motiv-
ational processes that are typically disrupted by stressors.
The repeated measures two-way ANOVA revealed a geno-
type × injection interaction (F(3,31) = 4.846; p < 0.05). As
borne out by the follow-up comparisons, by the fifth injec-
tion, WT paraquat-treated mice had significantly lower
nestlet building scores relative to all other groups (p <
0.05; Fig. 2b). Once again, the parallel G2019S experiment
confirmed the paraquat-induced reduction in home-cage
activity (F(1,58) = 7.60, p < 0.05) and nestlet building score
(F(1,108) = 26.41, p < 0.05) in WT mice but found that
the transgenic G2019S mutation had no influence on
these parameters (Fig. 2c, d).
LRRK2 KO blunted corticosterone elevations but not
BDNF or 5-HT1A changes in paraquat-exposed mice
Plasma corticosterone was assessed as an index of gen-
eral “stress state” of mice and is also a useful measure
that usually correlates with inflammatory sickness pro-
files. Once again, a significant genotype × injection inter-
action was evident (F(1,32) = 3.883, p = 0.05). Paralleling
the sickness syndrome, Fig. 3 shows that paraquat clearly
had a stressor-like effect as reflected by markedly ele-
vated plasma corticosterone levels in WT mice, relative
to saline injection; however, this effect was dramatically
blunted in the LRRK2 KOs (p < 0.05; Fig. 3a). The
transgenic G2019S study confirmed a significant main
effect of paraquat (F(1,20) = 8.67, p < 0.05) and genotype
(F(1,20) = 24.44, p < 0.05) on plasma corticosterone (Fig.
3b). Indeed, as shown in Fig. 3a, b, paraquat once again
significantly increased corticosterone levels (p < 0.05),
but most strikingly the G2019S overexpressing
Fig. 1 An initial study that involved intra-SNc LPS (2 μg) infusion followed by paraquat administration (10 mg/kg; ip) revealed that wild-type (WT)
mice displayed signs of extreme sickness, with a significant number (6/9) of mice either died outright or had to be euthanized (owing to moribund
presentation) by the ninth injection. In contrast, the mortality rate was reduced in LRRK2 knockout (KO) mice, such that only 1/6 reached end state
following the LPS + paraquat regimen. (a) The follow-up study showed that in the absence of LPS and with a reduced paraquat injection regimen,
paraquat-treated WT mice still displayed significant (albeit less) pathological signs in terms of ratings of sickness (b, c) and weight loss (d, e) by their
sixth paraquat injection. Importantly, once again this effect was prevented by LRRK2 KO (b, d). However, the G2019S (GS-Tg) transgenic mice did not
significantly differ from WT animals in terms of either sickness (c) or weight loss (e). Sickness was calculated as a composite score by
blind raters including ptosis, piloerection, lethargy, and curled body posture. *p < 0.05, relative to respective controls
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transgenic mice displayed further elevated levels of the
stress hormone. In fact, G2019S mice even had signifi-
cantly elevated basal levels of corticosterone, relative to
their WT counterparts (p < 0.05).
In addition to the stressor-like effects of paraquat on
corticosterone, similar alterations were observed with re-
gard to levels of the trophic factor, brain-derived neuro-
trophic factor (BDNF), within the striatum (Fig. 3c, d).
Indeed, striatal levels of BDNF were found to be reduced
by paraquat treatment in both the LRRK2 KO (F(1,22) =
4.76, p < 0.05) and G2019S (F(1,15) = 5.81, p < 0.05)
studies. Moreover, G2019S mice had basally reduced
striatal BDNF levels (F(1,15) = 6.72, p < 0.05). However,
LRRK2 deficiency did not further impact levels of the
growth factor, but the transgenic G2019S mutation did
significantly further reduce BDNF within the striatum,
relative to their WT counterparts (p < 0.05). In contrast
to the striatum, no significant changes in SNc levels of
BDNF were evident in either of the studies.
As a further measure of the potential role of LRRK2 on
stress-related processes, we assessed 5-HT1A levels in the
hippocampus, which has been implicated in depression
and anxiety that accompany PD [35]. To this end, al-
though neither paraquat nor LRRK2 KO affected hippo-
campal 5-HT1A levels of the receptor were altered by the
G2019S mutation (F(1,15) = 30.03, p < 0.05; Fig. 3e, f ).
Specifically, as shown in Fig. 3f, basal 5-HT1A levels were
significantly increased in the G2019S transgenic mutants,
relative to their WT littermates (p < 0.05).
Finally, the chemokine receptor, CX3CR1, was
assessed as an index of inflammatory cell changes. In-
deed, engagement of the CX3CR1 receptor on microglia
by its ligand, fractalkine, has been reported to maintain
a basal microglial phenotype and, in fact, might act in an
anti-inflammatory capacity [40]. To this end, SNc levels
of the chemokine receptor, CX3CR1 (which is found on
microglia and infiltrating macrophages), did vary as a
function of genotype (F(1,17) = 6.99, p < 0.05; Fig. 4a).
Although paraquat had no effect on CX3CR1, levels of
the inflammatory regulator were basally elevated by
LRRK2 KO (p < 0.05; Fig. 4a). Hence, endogenous
LRRK2 may act to restrict fractalkine signaling. In con-
trast, G2019S had no significant influence on SNc
CX3CR1 levels (Fig. 4b).
Fig. 2 Wild-type (WT) mice displayed a significant reduction in home-cage activity by the fifth paraquat injection (10 mg/kg; ip), and this effect
was reversed by LRRK2 knockout (KO) (a) but unaffected by G2019S (GS-Tg) transgenic overexpression (c). As a measure of nesting behavior,
which requires fine motor skills and is influenced by stress, nestlet building was assessed in the 24 h following the fifth paraquat injection.
Paraquat treatment markedly reduced nest building in WT mice, whereas LRRK2 KO prevented this deficit (b) but was unaffected by G2019S
mutation (d). *p < 0.05, relative to respective controls
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LRRK2 KO prevented the pathological effects of paraquat
within the periphery
An additional study was conducted to assess periph-
eral organ changes, and this experiment was restricted
to LRRK2 KOs, given that G2019S had few effects on
parameters of paraquat toxicity. This study sought to
assess whether the sickness changes induced were
associated with changes in the periphery, namely, cir-
culating IL-6 and changes in organ weight (indicative
of atrophy) and inflammatory factor expression
(WAVE2 and CX3CR1; indicative of inflammatory cell
migration and potential tissue remodeling). Accord-
ingly, paraquat injection parameters identical to the
aforementioned studies were utilized in 6–8-month--
old mice. Moving from the brain into the periphery,
we took gross measures of organ weight of the liver,
lungs, and spleen. These yielded significant genotype
× injection interactions for the liver (F(1,32) = 6.381,
p < 0.05; Fig. 5a) and lungs (F(1,32) = 4.369, p <
0.05; Fig. 5c). In the liver, paraquat reduced organ
weight in WT animals (p < 0.05; Fig. 5a) and LRRK2
KO prevented this effect. In the lung, paraquat in-
creased organ weight (p < 0.05) and again, this effect
was prevented by LRRK2 ablation (Fig. 5c). The
former effect could be related to liver atrophy,
whereas the latter effect could be attributable to
Fig. 3 The paraquat treatment regimen (black bars) induced an elevation of plasma corticosterone levels, relative to saline treatment (white bars),
and this elevation was significantly blunted in LRRK2 knockout (KO) mice (a). The G2019S (GS-Tg) transgenic mutation alone induced a significant
corticosterone elevation that was similar to that induced by paraquat in non-transgenic mice (b). In both the LRRK2 KO and G2019S studies,
paraquat significantly reduced striatal levels of BDNF in the absence of any effect of genotype (c, d). While hippocampal 5-HT1A levels were not
affected by paraquat or LRRK2 KO (e), the G2019S mutation did elevate 5-HTIA, relative to saline treatment (f). *p < 0.05, relative to respective
saline-treated controls, +p < 0.05, difference between genotypes
Fig. 4 Substantia nigra (SNc) levels of the chemokine receptor, CX3CR1, which is selectively found on microglia were significantly increased in
LRRK2 knockout (KO) mice (a), but were unaffected by the G2019S (GS-Tg) transgenic mutation (b). In no case did paraquat administration affect
SNc levels of CX3CR1. *p < 0.05, difference between genotypes
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LRRK2 preventing the expected infiltration of im-
mune cells and pneumatic inflammation that charac-
terizes paraquat’s typical lung toxicity. No significant
differences were observed for the spleen.
Surprisingly, in no case did organ levels of CX3CR1 vary
as a function of the treatments (data not shown). Yet
interestingly, levels of the actin regulatory factor, WAVE2,
which is crucial for immune cell migration and phagocy-
totic responses did vary within the lungs as function of a
genotype × injection interaction (F(1,12) = 5.752, p < 0.05;
Fig. 5d). In this case, paraquat reduced WAVE2 levels in
the lungs of WT mice but had no effect in the LRRK2
KOs, which already has basally suppressed levels of
WAVE2 (p < 0.05). Within the liver, paraquat modestly
(albeit not significantly) raised WAVE2 levels; but again, a
dramatic effect was evident as a function genotype
(F(1,12) = 4.703, p < 0.05; Fig. 5b), such that LRRK2 null
mice displayed lower levels relative to their WT counter-
parts (p < 0.05; Fig. 5b). No significant differences were
noted within the spleen, indicating some degree of
specificity in the paraquat and LRRK2 KO effects at the
organ level.
Finally, we assessed plasma cytokine levels and found
significant variations in IL-6 as a function of a genotype
× injection interaction (F(1,29) = 5.267, p < 0.05). The
follow-up comparisons confirmed that circulating IL-6
was significantly elevated in paraquat-treated WT mice
(p < 0.05), but that this effect was completely absent in
the LRRK2 null mice (Fig. 5e).
Discussion
LRRK2 is a large and complex gene that has been impli-
cated in not only PD, but also other diseases that have
an inflammatory component [41, 42]. It is thought to
have fundamental immune functions, such as the regula-
tion of monocyte and lymphocyte trafficking [9, 10], and
a couple of reports indicate that LRRK2 is important for
the neurodegenerative effects of toxicants, such as
MPTP and rotenone [12, 25]. Yet, the role of LRRK2 in
the context of paraquat exposure has not been explored,
Fig. 5 Assessment of gross organ weight revealed that paraquat reduced liver weight (a), while increasing lung weight (c) in wild-type (WT)
mice, but these changes were completely absent in LRRK2 knockout (KO) mice. Levels of the inflammatory actin regulator protein, WAVE2, were
reduced in the liver of LRRK2 null mice, relative to WT animals (b). Whereas WAVE2 levels in the lungs were reduced by paraquat in WT mice, no
such effect was apparent in LRRK2 KOs (d). Finally, paraquat provokes a significant elevation of plasma IL-6 in WT mice, but LRRK2 KO prevented
this effect (e). *p < 0.05, relative to respective saline-treated controls; +p < 0.05 differences between genotypes
Rudyk et al. Journal of Neuroinflammation          (2019) 16:120 Page 8 of 13
nor is it known how the gene might affect general in-
flammatory toxicity and stress processes. This is an im-
portant overlooked issue since PD, and in fact, virtually
all neurological conditions are typically associated with
marked stress and behavioral comorbidity and the same
environmental toxins that have been linked to PD also
cause inflammatory toxicity. In fact, we are interested in
not only PD-like motor effects but also general sickness
responses and the possibility that LRRK2 could be a me-
diator of fundamental body reactions to environmental
stressors, particularly those that elicit oxidative and in-
flammatory distress, as paraquat does.
Our previous work showed that 2–3-month-old mice
treated with paraquat displayed modest sickness behav-
iors which resolved rapidly, but these mice went on to
display PD-like motor impairments [19, 34]. However, a
small subset (~ 10–15%) of mice often does not fully re-
cover and, hence, is removed from the experiment. In
the present study, using moderately older mice (6–8
months), we found a much greater (~ 70%) mortality
rate which became apparent after the sixth paraquat in-
jection. Markedly, LRRK2 null mice were protected from
this enhanced mortality, raising the possibility that the
gene is involved in general toxicity. Hence, we reduced
the number of paraquat injections with an aim of asses-
sing whether LRRK2 is critical for the systemic stress
and inflammatory toxicity of paraquat in older animals.
Consistent with our previous findings [43], paraquat
acted as a systemic stressor, as evidenced by its elevation
of plasma corticosterone and IL-6, provocation of sick-
ness behavior, and disturbances in nesting and motor be-
haviors. Indeed, we and others have shown that
paraquat-induced increased pro-inflammatory cytokine
levels in the brain, as well as in the lungs and in serum
[19, 32, 44–46]. We know that collectively these cyto-
kines and corticosterone can act additively or even syn-
ergistically to provoke behavioral disturbances and
neurochemical alterations and at high enough concen-
tration can cause cellular death [47, 48]. Accordingly,
paraquat presently induced peripheral changes indicative
of inflammatory pathology. Just as was the case for the
mortality, LRRK2 KO prevented these outcomes. Hence,
indicating for the first time LRRK2 involvement in
toxicant-induced sickness and stress factor responses
and raising the possibility that it might influence brain
circuits that are crucial for prototypical illness (e.g., shiv-
ering, fever, piloerection, ptosis) and stressor-relevant
social species-specific behaviors [49, 50]. In effect,
LRRK2 might be an important mediator of general in-
flammatory tone and brain-immune dialogue in the face
of environmental insults.
Bi-directional communication between peripheral or-
gans and the brain involving immune factors, such as
cytokines or through neural fibers, has been well
established. Indeed, cytokines can activate brain regions
through vagal afferents or infiltration of the parenchyma
through saturable transport mechanisms [51, 52]. For in-
stance, nigral-vagal communication, which has been im-
plicated in the gastrointestinal alterations in PD patients,
may serve as a route for the spread of pathology, such as
α-synuclein aggregates [53, 54]. In fact, direct stimula-
tion of substantia nigra neurons was shown to activate
the dorsal vagal complex, which in turn, regulated
gastrointestinal functioning, and this communication
was disrupted by paraquat administration [55]. As
well, LRRK2 could play a role in gastric pathology in
PD patients given that the LRRK2 MUC19 mutation
confers risk of Chron’s disease [56] and that LRRK2
R1411G mutant mice display early gastrointestinal
disturbances [57].
Besides the brain, the main target organ for paraquat
is the lung, with the toxicant causing considerable pul-
monary fibrosis and accumulation of inflammatory im-
mune infiltrates [46, 58]. The increased lung weight
presently observed with paraquat treatment is consistent
with the edema and accumulation of immune cell infil-
trates that has previously been reported with paraquat
intoxication [59]. Moreover, the reduction in WAVE2
lung levels we observed might reflect general damage to
tissue, or alternatively, variations in cell trafficking.
WAVE2 is known to be crucial for the actin
re-modelling in immune cells that are required for traf-
ficking and processes such as phagocytosis [36, 60]. In-
deed, LRRK2 was reported to control phagocytic
immune cell responses through the actin regulatory fac-
tor, WAVE2 [36], which also may be fundamental for
basic inflammatory cell trafficking and inflammatory
phenotype [60, 61]. The fact that LRRK2 knockout mice
had lower overall basal organ levels of WAVE2 is
consistent with a role for LRRK2 in regulating
WAVE2-dependent inflammatory processes [36, 60].
Specifically, WAVE2 would be expected to underlie
phenotypic shifts in the activation state of inflammatory
cells (particularly macrophages) and if this is regulated
by LRRK2, then its deficiency would limit inflammatory
cell migration into organs. Yet, the reduction in lung
WAVE2 induced by paraquat in wild-type mice is hard
to reconcile; it conceivably could reflect an increased mi-
gration of inflammatory immune cells from out of the
lung into the circulatory or lymphatic system. Alterna-
tively, alveolar macrophages are particularly vulnerable
to paraquat toxicity and the reduction in WAVE2 could
actually reflect a loss of these cells [62]. Interestingly,
levels of the fractalkine receptor, CX3CR1, were not af-
fected in the lung or other peripheral tissues but were
basally elevated in the SNc of LRRK2 KOs. Emerging
evidence suggests that CX3CR1 can act as a distress sig-
nal that mobilizes immune cells [63], as well as a
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regulator of basal immune cell housekeeping functions
[64–66]. Our findings suggest clearly contrasting roles
for WAVE2 and fractalkine and are consistent with the
notion that the former is aligned with pro-inflammatory
responses, and latter may foster more of an
anti-inflammatory or “normal” homeostatic phenotype
for microglia and peripheral immune cells.
Brain-lung interactions readily occur in the context
of inflammatory pathology. For instance, direct inflam-
mation of the lung via monocrotaline (used to induce
pulmonary hypertension) causes microglial activation
within the brain and this effect was reversed by
anti-inflammatory (minocycline) treatment [67]. Simi-
larly, brain pathology induced by traumatic brain injury
provoked lung pathology characterized by neutrophil
infiltration, alveolar thickening, and fibrin deposition
[68]. Also, in addition to the lung, we found that
paraquat-reduced liver weight, which is consistent with
organ atrophy from repeatedly dealing with detoxifica-
tion and excretion of the toxicant. Of course, an im-
portant caveat of this study is that organ histology was
not performed, so it is unclear as to the extent to which
paraquat might have directly damaged the tissues.
It was particularly interesting that the G2019S trans-
genic mutation did not affect overall toxicity, but that
these mice did show signs of enhanced basal stress tone.
Specifically, corticosterone levels and hippocampal
5-HT1A were basally increased, and also simply inject-
ing the saline vehicle reduced home-cage activity levels
in transgenic G2019S animals (compared to their WT
littermates). The fact that the LRRK2 deficiency reduced
the corticoid response, but the G2019S mutation in-
creased it suggests a clear divergence in the role of en-
dogenous LRRK2 vs. it is the increased kinase activity
that occurs with G2019S mutation. LRRK2 is a complex
protein with kinases activity, as well as non-kinase func-
tions that involve its facilitation of protein-protein inter-
actions. The G2019S mutation increases kinase activity
but should not affect non-kinase mechanisms, suggest-
ing a possible selective role for kinase-mediated actions
in promoting corticoid responses (possibly by phosphor-
ylating CRH or by stimulating p38 or JNK). Alterna-
tively, knockout of endogenous LRRK2 clearly blunted
the HPA response and this could stem from reduced
kinase activity, as well as potential reductions in pro-
tein signaling pathways, most notably, p38, JNK,
interferon gamma, as well as a number of RAB pro-
teins that control vesicular trafficking, autophagy, and
lysosomal functioning [69]. We and others did find
that G2019S overexpression markedly altered basal
and immune challenge evoked dopaminergic activity
within the striatum [70–72]. But again, these trans-
genic mice did not show changes in pathology or in-
flammatory parameters, including sickness behaviors
or circulating cytokines. Hence, forced G2019S over-
expression clearly has functional effects but not ne-
cessarily those that would be obviously aligned with
inflammatory damage or neurodegeneration.
The stress phenotype of the G2019S mice is intriguing
in that it raises the possibility that the mutation could
specifically favor the development of psychiatric distur-
bances, which are commonly co-morbid with PD [72–
74]. Indeed, the basal elevation of 5-HT1A we observed
in G2019S mutants is consistent with a recent report
that also found these mice to display anxiety and
depressive-like behaviors [35]. The LRRK2 BAC G2019S
mice also showed decreased dopamine release [70],
which could certainly contribute to behavioral distur-
bances. Similarly, the basally increased corticosterone we
observed in the G2019S mice could conceivably have
been modulating behaviors. It is important to note that
unlike these 6–8-month-old animals, we recently found
that 2-month-old G2019S overexpressing mice had no
such basal behavioral or corticoid differences [72], sug-
gesting that age is critical for the manifestation of the
“stress” phenotype.
There is a reason to believe that the G2019S mutation
has a modulatory role with regard to neuroplasticity. For
instance, it was reported that aged 8–9 months G2019S
over-expressing mice had impaired plasticity of medium
spiny striatal neurons [75]. The G2019S mutation was
also linked to altered hippocampal LTD [76], along with
diminished adult hippocampal neurogenesis and den-
dritic arborization and spine numbers in newly gener-
ated neurons [77]. Yet, although paraquat did reduce
BDNF, the present results found that neither LRRK2 KO
nor the G2019S mutation affected hippocampal or stri-
atal levels of the growth factor.
It is important to underscore the differences between
bacterial artificial chromosome (BAC) G2019S trans-
genic over-expressers (as presently used), and targeted
G2019S knock-in mice. Of course, with BAC G2019S
overexpression, mutant LRRK2 levels are artificially in-
duced plus there is still some expression of WT LRRK2.
Hence, interactions between the two could conceivably
take place, and we are essentially looking at the com-
bined effects of ~ 6–8-fold over-expression of the mu-
tant G2019S transgene in the context of the normal
expression of WT LRRK2. In contrast, the knock-in
form of G2019S entirely replaces the WT form and
elicits more “normal” levels of the gene.
Conclusions
We found that 6–8-month-old mice had marked sick-
ness and behavioral disturbances in response to paraquat
and LRRK2 knockout totally prevented these effects. Al-
though it is likely that immune cells and/or inflamma-
tory factors played a role in these outcomes, the
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elevation of corticosterone may also be important since
it is known to modulate inflammatory processes and re-
covery from sickness [78]. Of course, the fact that the
paraquat-induced cytokine changes (IL-6) could actually
be driving the corticosterone response makes it difficult
to disentangle the individual effects of cytokines vs hor-
monal changes. Whatever the case, endogenous LRRK2
appears to be critically involved in paraquat provoked
widespread pathology and is specifically modulating the
downstream effects at multiple targets. Curiously, over-
expression of the G2019S transgene did not affect para-
quat toxicity but did appear to convey a “stress-like”
phenotype, at least with regard to corticosterone, hippo-
campal 5-HT1A, and home cage activity. These data
clearly suggest a novel role for LRRK2 in modulating
general inflammatory and sickness profiles in response
to a systemic environmental stressor. Not only is this
important from a mechanistic prospective, but also clin-
ically given that LRRK2 inhibitors are already being ex-
plored. Ultimately, endogenous LRRK2 appears to be
important for processes aligned with toxicological
threats and sickness responses, whereas the G2019S mu-
tation may modulate basal stress state.
Abbreviations
Bac: Bacterial artificial chromosome; BDNF: Brain derived neurotropic factor;
KO: Knockout; LPS: Lipopolysaccharide; LRRK2: Leucine-rich repeat kinase-2;
MMx: Micromax; PD: Parkinson’s disease; WT: Wild-type
Acknowledgements
This work was supported by a grant from the Canadian Institutes of Health
Research (CIHR) to S.H. and a CIHR to our CLINT (Canadian LRRK2 in
inflammation team) group. CLINT membership is comprised of E. Schurr,
Earl Brown, Derrick Gibbings, Shawn Hayley, David Park, Dana C. Philpott,
John D. Rioux, and Michael Schlossmacher.
Funding
This work was supported by CIHR.
Availability of data and materials
All data supporting the conclusions of this article will be included in this
article.
Authors’ contributions
This work contains significant contributions from each author. CR ,ZD, SH
conceived and designed the experiments. CR and ZD performed the
experiments. SH contributed reagents/materials/analysis tools. : CR, ZD, and
SH analyzed the data and wrote the paper. All authors read and approved
the final manuscript.
Ethics approval and consent to participate
The Carleton University Committee for Animal Care approved all experimental
procedures and complied with the guidelines set out by the Canadian Council
for the Use and Care of Animals in Research.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Received: 16 January 2019 Accepted: 18 April 2019
References
1. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson
disease. Nat Rev Neurosci. 2017;18:435–50.
2. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s
disease: diagnosis and management. Lancet Neurol. 2006;5:235–45.
3. Lesage S, Dürr A, Tazir M, Lohmann E, Leutenegger A-L, Janin S, et al. LRRK2
G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J
Med. 2006;354:422–3.
4. Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, et al.
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
Neurology. 2006;67:1786–91.
5. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati
M, et al. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews.
N Engl J Med. 2006;354:424–5. https://doi.org/10.1056/NEJMc055509.
6. Cook DA, Kannarkat GT, Cintron AF, Butkovich LM, Fraser KB, Chang J, et al.
LRRK2 levels in immune cells are increased in Parkinson’s disease. NPJ Park
Dis. 2017;3:11.
7. Ho DH, Je AR, Lee H, Son I, Kweon H-S, Kim H-G, et al. LRRK2 kinase activity
induces mitochondrial fission in microglia via Drp1 and modulates
neuroinflammation. Exp Neurobiol. 2018;27:171–80.
8. Russo I, Bubacco L, Greggio E. LRRK2 and neuroinflammation: partners in
crime in Parkinson’s disease? J Neuroinflammation. 2014;11:52.
9. Ma B, Xu L, Pan X, Sun L, Ding J, Xie C, et al. LRRK2 modulates microglial
activity through regulation of chemokine (C-X3-C) receptor 1 -mediated
signalling pathways. Hum Mol Genet. 2015;25:3515–23.
10. Kozina E, Sadasivan S, Jiao Y, Dou Y, Ma Z, Tan H, et al. Mutant LRRK2
mediates peripheral and central immune responses leading to
neurodegeneration in vivo. Brain. 2018:awy077–7 https://doi.org/10.1093/
brain/awy077.
11. Rudyk CA, McNeill J, Prowse N, Dwyer Z, Farmer K, Litteljohn D, et al. Age
and chronicity of administration dramatically influenced the impact of low
dose paraquat exposure on behavior and hypothalamic-pituitary-adrenal
activity. Frontiers in Aging Neuroscience. 2017;9(222) http://journal.
frontiersin.org/article/10.3389/fnagi.2017.00222.
12. Karuppagounder SS, Xiong Y, Lee Y, Lawless MC, Kim D, Nordquist E, et
al. LRRK2 G2019S transgenic mice display increased susceptibility
to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated
neurotoxicity. J Chem Neuroanat. 2016;76(Pt B):90–7. https://doi.org/10.
1016/j.jchemneu.2016.01.007.
13. Daher JPL, Volpicelli-Daley LA, Blackburn JP, Moehle MS, West AB.
Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in
LRRK2-deficient rats. Proc Natl Acad Sci U S A. 2014;111:9289–94. https://doi.
org/10.1073/pnas.1403215111.
14. Breckenridge CB, Berry C, Chang ET, Sielken RL, Mandel JS. Association
between Parkinson’s disease and cigarette smoking, rural living, well-water
consumption, farming and pesticide use: systematic review and meta-
analysis. PLoS One. 2016;11:e0151841.
15. Baltazar MT, Dinis-Oliveira RJ, de Lourdes Bastos M, Tsatsakis AM, Duarte JA,
Carvalho F. Pesticides exposure as etiological factors of Parkinson’s disease
and other neurodegenerative diseases - a mechanistic approach. Toxicol
Lett. 2014;230:85–103.
16. Kamel F. Epidemiology. Paths from pesticides to Parkinson’s. Science. 2013;
341:722–3.
17. Freire C, Koifman S. Pesticide exposure and Parkinson’s disease:
Epidemiological evidence of association. Neuro Toxicol. 2012;33:947–71.
18. Ishola IO, Akinyede AA, Adeluwa TP, Micah C. Novel action of vinpocetine in
the prevention of paraquat-induced parkinsonism in mice: involvement of
oxidative stress and neuroinflammation. Metab Brain Dis. 2018.
19. Mangano EN, Peters S, Litteljohn D, So R, Bethune C, Bobyn J, et al.
Granulocyte macrophage-colony stimulating factor protects against
substantia nigra dopaminergic cell loss in an environmental toxin model of
Parkinson’s disease. Neurobiol Dis. 2011;43:99–112. https://doi.org/10.1016/j.
nbd.2011.02.011.
Rudyk et al. Journal of Neuroinflammation          (2019) 16:120 Page 11 of 13
20. Rappold PM, Cui M, Chesser AS, Tibbett J, Grima JC, Duan L, et al. Paraquat
neurotoxicity is mediated by the dopamine transporter and organic cation
transporter-3. Proc Natl Acad Sci U S A. 2011;108:20766–71. https://doi.org/
10.1073/pnas.1115141108.
21. Jiao Y, Lu L, Williams RW, Smeyne RJ. Genetic dissection of strain dependent
paraquat-induced neurodegeneration in the substantia nigra pars
compacta. PLoS One. 2012;7:e29447. https://doi.org/10.1371/journal.pone.
0029447.
22. Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, et al.
Genetic modification of the association of paraquat and Parkinson’s disease.
Mov Disord. 2012;27:1652–8. https://doi.org/10.1002/mds.25216.
23. Ritz BR, Manthripragada AD, Costello S, Lincoln SJ, Farrer MJ, Cockburn M, et
al. Dopamine transporter genetic variants and pesticides in Parkinson’s
disease. Environ Health Perspect. 2009;117:964–9.
24. Nixon AM, Meadowcroft MD, Neely EB, Snyder AM, Purnell CJ, Wright J, et
al. HFE genotype restricts the response to paraquat in a mouse model of
neurotoxicity. J Neurochem. 2018;145:299–311.
25. Lee J-WW, Cannon JR. LRRK2 mutations and neurotoxicant susceptibility.
Exp Biol Med. 2015;240:752–9. https://doi.org/10.1177/1535370215579162.
26. Lee AJ, Wang Y, Alcalay RN, Mejia-Santana H, Saunders-Pullman R, Bressman
S, et al. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of
non-Ashkenazi Jewish ancestry. Mov Disord Off J Mov Disord Soc. 2017;32:
1432–8.
27. X R, S B-C, C B, MR C. The role of monogenic genes in idiopathic
Parkinson’s disease. Neurobiol Dis. 2019;124:230–9.
28. Kluss JH, Mamais A, Cookson MR. LRRK2 links genetic and sporadic
Parkinson’s disease. Biochem Soc Trans. 2019;5.
29. Volpicelli-Daley LA, Abdelmotilib H, Liu Z, Stoyka L, Daher JP, Milnerwood
AJ, Unni VK, Hirst WD, Yue Z, Zhao HT, Fraser K, Kennedy RE, West AB.
G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into
Inclusions in Neurons. J Neurosci. 2016;36(28):7415–27.
30. Garcia-Miralles M, Coomaraswamy J, Häbig K, Herzig MC, Funk N, Gillardon
F, Maisel M, Jucker M, Gasser T, Galter D, Biskup S. No dopamine cell loss or
changes in cytoskeleton function in transgenic mice expressing
physiological levels of wild type or G2019S mutant LRRK2 and in human
fibroblasts. PLoS One. 2015;10(4):e0118947.
31. Moehle MS, Daher JP, Hull TD, Boddu R, Abdelmotilib HA, Mobley J,
Kannarkat GT, Tansey MG, West AB. The G2019S LRRK2 mutation increases
myeloid cell chemotactic responses and enhances LRRK2 binding to actin-
regulatory proteins. Hum Mol Genet. 2015;24(15):4250–67.
32. Mangano EN, Litteljohn D, So R, Nelson E, Peters S, Bethune C, et al.
Interferon-γ plays a role in paraquat-induced neurodegeneration
involving oxidative and proinflammatory pathways. Neurobiol Aging.
2012;33:1411–26.
33. Litteljohn D, Nelson E, Hayley S. IFN-gamma differentially modulates
memory-related processes under basal and chronic stressor conditions.
Front Cell Neurosci. 2014;8:391. https://doi.org/10.3389/fncel.2014.00391.
34. Litteljohn D, Mangano E, Shukla N, Hayley S. Interferon-gamma deficiency
modifies the motor and co-morbid behavioral pathology and
neurochemical changes provoked by the pesticide paraquat. Neuroscience.
2009;164:1894–906. https://doi.org/10.1016/j.neuroscience.2009.09.025.
35. Lim J, Bang Y, Choi J-H, Han A, Kwon M-S, Liu KH, et al. LRRK2 G2019S
induces anxiety/depression-like behavior before the onset of motor
dysfunction with 5-ht1a receptor upregulation in mice. J Neurosci. 2018;38:
1611–21. https://doi.org/10.1523/JNEUROSCI.4051-15.2017.
36. Kim KS, Marcogliese PC, Yang J, Callaghan SM, Resende V, Abdel-Messih E,
et al. Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex
stabilization is altered in Parkinson’s disease. Proc Natl Acad Sci U S A. 2018.
37. Mangano EN, Hayley S. Inflammatory priming of the substantia nigra
influences the impact of later paraquat exposure: neuroimmune
sensitization of neurodegeneration. Neurobiol Aging. 2009;30:1361–78.
https://doi.org/10.1016/j.neurobiolaging.2007.11.020.
38. Hayley S, Lacosta S, Merali Z, Van Rooijen N, Anisman H. Central monoamine
and plasma corticosterone changes induced by a bacterial endotoxin:
Sensitization and cross-sensitization effects. Eur J Neurosci. 2001;13:1155–65.
39. Paumier KL, Sukoff Rizzo SJ, Berger Z, Chen Y, Gonzales C, Kaftan E, et al.
Behavioral characterization of A53T mice reveals early and late stage deficits
related to Parkinson’s disease. PLoS One. 2013;8:e70274.
40. Szepesi Z, Manouchehrian O, Bachiller S, Deierborg T. Bidirectional
microglia–neuron communication in health and disease. Front Cell
Neurosci. 2018.
41. Dzamko NL. LRRK2 and the immune system. Adv Neurobiol. 2017;14:123–43.
42. Lewis PA, Manzoni C. LRRK2 and human disease: a complicated question or
a question of complexes? Sci Signal. 2012;5:pe2.
43. Rudyk C, Litteljohn D, Syed S, Dwyer Z, Hayley S. Paraquat and
psychological stressor interactions as pertains to Parkinsonian co-morbidity.
Neurobiol Stress. 2015;2:85–93.
44. Harchegani AL, Hemmati AA, Nili-Ahmadabadi A, Darabi B, Shabib S.
Cromolyn sodium attenuates paraquat-induced lung injury by modulation
of proinflammatory cytokines. Drug Res (Stuttg). 2017;67:283–8.
45. Costa KM, Maciel IS, Kist LW, Campos MM, Bogo MR. Pharmacological
inhibition of CXCR2 chemokine receptors modulates paraquat-induced
intoxication in rats. PLoS One. 2014;9:e105740.
46. Shen H, Wu N, Wang Y, Zhao H, Zhang L, Li T, et al. Chloroquine attenuates
paraquat-induced lung injury in mice by altering inflammation, oxidative
stress and fibrosis. Int Immunopharmacol. 2017;46:16–22.
47. Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H. Synergistic effects of
interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: central
monoamine, corticosterone, and behavioral variations.
Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2000;22:
566–80.
48. Hayley S. The neuroimmune-neuroplasticity interface and brain pathology.
Front Cell Neurosci. 2014;8:419. https://doi.org/10.3389/fncel.2014.00419.
49. Griton M, Konsman JP. Neural pathways involved in infection-induced
inflammation: recent insights and clinical implications. Clin Auton Res Off J
Clin Auton Res Soc. 2018;28:289–99.
50. Hayley S, Brebner K, Lacosta S, Merali Z, Anisman H. Sensitization to the
effects of tumor necrosis factor-alpha: neuroendocrine, central monoamine,
and behavioral variations. J Neurosci. 1999;19:5654–65. https://doi.org/10.
1523/jneurosci.3567-08.2009.
51. Banks WA. The blood-brain barrier in neuroimmunology: tales of separation
and assimilation. Brain Behav Immun. 2015;44:1–8.
52. Zielinski MR, Dunbrasky DL, Taishi P, Souza G, Krueger JM. Vagotomy
attenuates brain cytokines and sleep induced by peripherally administered
tumor necrosis factor-α and lipopolysaccharide in mice. Sleep. 2013;36:
1227–38 1238A.
53. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T, et al.
Direct evidence of Parkinson pathology spread from the gastrointestinal
tract to the brain in rats. Acta Neuropathol. 2014;128:805–20.
54. Garrido-Gil P, Rodriguez-Perez AI, Dominguez-Meijide A, Guerra MJ,
Labandeira-Garcia JL. Bidirectional neural interaction between central
dopaminergic and gut lesions in Parkinson’s disease models. Mol Neurobiol.
2018;55:7297–316.
55. Anselmi L, Toti L. A Nigro−Vagal pathway controls gastric motility and is
affected in a rat model of parkinsonism. Gastroenterology. 2017.
56. Vora P, McGovern DPB. LRRK2 as a negative regulator of NFAT: implications
for the pathogenesis of inflammatory bowel disease. Expert Rev Clin
Immunol. 2012.
57. Bichler Z, Lim HC, Zeng L, Tan EK. Non-Motor and motor features in LRRK2
transgenic mice. PLoS One. 2013.
58. Schapochnik A, da Silva MR, Leal MP, Esteves J, Hebeda CB, Sandri S, et al.
Vitamin D treatment abrogates the inflammatory response in paraquat-
induced lung fibrosis. Toxicol Appl Pharmacol. 2018;355:60–7.
59. Qian J, Liu L, Chen L, Lu X, Zhu C. Increased toll-like receptor 9 expression is
associated with the severity of paraquat-induced lung injury in mice. Hum
Exp Toxicol. 2015;34:430–8.
60. Nolz JC, Gomez TS, Zhu P, Li S, Medeiros RB, Shimizu Y, et al. The WAVE2
complex regulates actin cytoskeletal reorganization and CRAC-mediated
calcium entry during T cell activation. Curr Biol. 2006;16:24–34.
61. Ibarra N, Pollitt A, Insall RH. Regulation of actin assembly by SCAR/WAVE
proteins. Biochem Soc Trans. 2005;33:1243 LP–1246 http://www.
biochemsoctrans.org/content/33/6/1243.abstract.
62. Dusinská M, Kovaciková Z, Vallová B, Collins A. Responses of alveolar
macrophages and epithelial type II cells to oxidative DNA damage caused
by paraquat. Carcinogenesis. 1998;19(5):809–12.
63. Ma B, Xu L, Pan X, Sun L, Ding J, Xie C, et al. LRRK2 modulates microglial
activity through regulation of chemokine (C–X3–C) receptor 1–mediated
signalling pathways. Hum Mol Genet. 2016. https://doi.org/10.1093/hmg/
ddw194.
64. Sheridan GK, Murphy KJ. Neuron-glia crosstalk in health and disease:
fractalkine and CX3CR1 take centre stage. Open Biol. 2013;3:130181. https://
doi.org/10.1098/rsob.130181.
Rudyk et al. Journal of Neuroinflammation          (2019) 16:120 Page 12 of 13
65. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al.
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci.
2006;9:917–24.
66. Febinger HY, Thomasy HE, Pavlova MN, Ringgold KM, Barf PR, George AM,
et al. Time-dependent effects of CX3CR1 in a mouse model of mild
traumatic brain injury. J Neuroinflammation. 2015;12.
67. Sharma RK, Oliveira AC, Kim S, Rigatto K, Zubcevic J, Rathinasabapathy A, et
al. Involvement of neuroinflammation in the pathogenesis of
monocrotaline-induced pulmonary hypertension. Hypertens (Dallas, Tex
1979). 2018;71:1156–63. https://doi.org/10.1161/HYPERTENSIONAHA.118.
10934.
68. Lin HJ, Hsu CC, Chio CC, Tian YF, Lin MT, Lin TW, et al. Gamma-secretase
inhibitors attenuate neurotrauma and neurogenic acute lung injury in rats
by rescuing the accumulation of hypertrophic microglia. Cell Physiol
Biochem. 2018.
69. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science. 2018;
360(6384):36–7.
70. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, et al.
Enhanced striatal dopamine transmission and motor performance with
LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease
mutation G2019S. J Neurosci Off J Soc Neurosci. 2010;30:1788–97.
71. Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, et al.
Progressive dopaminergic alterations and mitochondrial abnormalities in
LRRK2 G2019S knock-in mice. Neurobiol Dis. 2015;78:172–95.
72. Litteljohn D, Rudyk C, Dwyer Z, Farmer K, Fortin T, Hayley S. The impact of
murine LRRK2 G2019S transgene overexpression on acute responses to
inflammatory challenge. Brain Behav Immun. 2018;67:246–56.
73. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment
of depression in Parkinson’s disease. Biol Psychiatry. 2003;54:363–75.
74. Lee J-W, Tapias V, Di Maio R, Greenamyre JT, Cannon JR. Behavioral,
neurochemical, and pathologic alterations in bacterial artificial chromosome
transgenic G2019S leucine-rich repeated kinase 2 rats. Neurobiol Aging.
2015;36:505–18.
75. Chou JS, Chen CY, Chen YL, Weng YH, Yeh TH, Lu CS, et al. (G2019S) LRRK2
causes early-phase dysfunction of SNpc dopaminergic neurons and
impairment of corticostriatal long-term depression in the PD transgenic
mouse. Neurobiol Dis. 2014.
76. Sweet ES, Saunier-Rebori B, Yue Z, Blitzer RD. The Parkinson’s disease-
associated mutation LRRK2-G2019S impairs synaptic plasticity in mouse
hippocampus. J Neurosci. 2015.
77. Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, Kent C, et al. Adult
neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice.
Neurobiol Dis. 2011.
78. Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and
its functional correlates: from HPA axis to glucocorticoid receptor
dysfunction. NIH Public Access; 2012.
Rudyk et al. Journal of Neuroinflammation          (2019) 16:120 Page 13 of 13
